{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:48:53Z","timestamp":1777560533910,"version":"3.51.4"},"reference-count":94,"publisher":"Elsevier","isbn-type":[{"value":"9780128097458","type":"print"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/bs.apha.2016.03.002","type":"book-chapter","created":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T02:08:42Z","timestamp":1462068522000},"page":"147-173","source":"Crossref","is-referenced-by-count":2,"title":["The Long and Winding Road"],"prefix":"10.1016","author":[{"given":"P.R.","family":"Lowenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2005.16.741","article-title":"Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses","volume":"16","author":"Abordo-Adesida","year":"2005","journal-title":"Human Gene Therapy"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0010","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ymthe.2004.08.025","article-title":"Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression","volume":"10","author":"Ali","year":"2004","journal-title":"Molecular Therapy"},{"issue":"16","key":"10.1016\/bs.apha.2016.03.002_bb0015","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-04-3434","article-title":"Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model","volume":"65","author":"Ali","year":"2005","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0020","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/pr.114.009456","article-title":"Dendritic cells as pharmacological tools for cancer immunotherapy","volume":"67","author":"Anguille","year":"2015","journal-title":"Pharmacological Reviews"},{"issue":"7","key":"10.1016\/bs.apha.2016.03.002_bb0025","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"18","key":"10.1016\/bs.apha.2016.03.002_bb0030","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/0008-5472.CAN-14-1203","article-title":"Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity","volume":"74","author":"Baker","year":"2014","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0035","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/S1740925X07000579","article-title":"Immunological thresholds in neurological gene therapy: Highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells","volume":"2","author":"Barcia","year":"2006","journal-title":"Neuron Glia Biology"},{"issue":"12","key":"10.1016\/bs.apha.2016.03.002_bb0040","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/sj.mt.6300305","article-title":"One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: Clinical implications","volume":"15","author":"Barcia","year":"2007","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14712598.2015.972361","article-title":"Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma","volume":"15","author":"Batich","year":"2015","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.it.2006.11.007","article-title":"What is the blood-brain barrier (not)?","volume":"28","author":"Bechmann","year":"2007","journal-title":"Trends in Immunology"},{"issue":"5","key":"10.1016\/bs.apha.2016.03.002_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1227\/NEU.0b013e3181f556ab","article-title":"Magnetic resonance imaging characteristics of glioblastoma multiforme: Implications for understanding glioma ontogeny","volume":"67","author":"Bohman","year":"2010","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00401-014-1319-6","article-title":"Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: Diagnostic and therapeutic implications","volume":"128","author":"Buczkowicz","year":"2014","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.apha.2016.03.002_bb0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fonc.2015.00147","article-title":"Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma","volume":"5","author":"Buczkowicz","year":"2015","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"10.1016\/bs.apha.2016.03.002_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/cne.21668","article-title":"CD11c\/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain","volume":"508","author":"Bulloch","year":"2008","journal-title":"The Journal of Comparative Neurology"},{"issue":"9","key":"10.1016\/bs.apha.2016.03.002_bb0075","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1523\/JNEUROSCI.16-09-03045.1996","article-title":"Immunological instability of persistent adenovirus vectors in the brain: Peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination","volume":"16","author":"Byrnes","year":"1996","journal-title":"The Journal of Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0306-4522(95)00068-T","article-title":"Adenovirus gene transfer causes inflammation in the brain","volume":"66","author":"Byrnes","year":"1995","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2016.03.002_bb0085","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1593\/neo.12794","article-title":"Plasmacytoid dendritic cells in the tumor microenvironment: Immune targets for glioma therapeutics","volume":"14","author":"Candolfi","year":"2012","journal-title":"Neoplasia"},{"issue":"13","key":"10.1016\/bs.apha.2016.03.002_bb0090","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1158\/1078-0432.CCR-09-0155","article-title":"Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity","volume":"15","author":"Candolfi","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apha.2016.03.002_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbi.2013.10.012","article-title":"Afferent and efferent immunological pathways of the brain. Anatomy, function and failure","volume":"36","author":"Carare","year":"2014","journal-title":"Brain, Behavior, and Immunity"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0100","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"issue":"8","key":"10.1016\/bs.apha.2016.03.002_bb0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0110","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.176.6.3566","article-title":"Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain","volume":"176","author":"Curtin","year":"2006","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0115","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1371\/journal.pmed.1000010","article-title":"HMGB1 mediates endogenous TLR2 activation and brain tumor regression","volume":"6","author":"Curtin","year":"2009","journal-title":"PLoS Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2016.03.002_bb0120","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-012-1018-0","article-title":"Brain dendritic cells: Biology and pathology","volume":"124","author":"D'Agostino","year":"2012","journal-title":"Acta Neuropathologica"},{"issue":"2","key":"10.1016\/bs.apha.2016.03.002_bb0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/bjc.2015.421","article-title":"Has the survival of patients with glioblastoma changed over the years?","volume":"114","author":"deSouza","year":"2016","journal-title":"British Journal of Cancer"},{"issue":"11","key":"10.1016\/bs.apha.2016.03.002_bb0130","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/15207","article-title":"Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials","volume":"5","author":"Dewey","year":"1999","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1016\/bs.apha.2016.03.002_bb0135","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cncr.28935","article-title":"Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies","volume":"121","author":"Field","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/bs.apha.2016.03.002_bb0140","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMe1313309","article-title":"Bevacizumab in glioblastoma\u2014still much to learn","volume":"370","author":"Fine","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/CCO.0000000000000135","article-title":"Perspectives for immunotherapy in glioblastoma treatment","volume":"26","author":"Finocchiaro","year":"2014","journal-title":"Current Opinion in Oncology"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)?","volume":"28","author":"Galea","year":"2007","journal-title":"Trends in Immunology"},{"issue":"7","key":"10.1016\/bs.apha.2016.03.002_bb0155","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1073\/pnas.1315943111","article-title":"Ischemic neurons recruit natural killer cells that accelerate brain infarction","volume":"111","author":"Gan","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1006\/mthe.2000.0140","article-title":"Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo","volume":"2","author":"Gerdes","year":"2000","journal-title":"Molecular Therapy"},{"issue":"8","key":"10.1016\/bs.apha.2016.03.002_bb0165","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/bs.apha.2016.03.002_bb0170","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc1403303","article-title":"Bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2016.03.002_bb0175","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11910-013-0346-3","article-title":"Brainstem glioma: A review","volume":"13","author":"Grimm","year":"2013","journal-title":"Current Neurology and Neuroscience Reports"},{"key":"10.1016\/bs.apha.2016.03.002_bb0180","first-page":"CD007415","article-title":"Temozolomide for high grade glioma","volume":"4","author":"Hart","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1227\/NEU.0000000000001035","article-title":"Combining 5-ALA fluorescence and intraoperative MRI in glioblastoma surgery: A histology-based evaluation","volume":"78","author":"Hauser","year":"2016","journal-title":"Neurosurgery"},{"issue":"10","key":"10.1016\/bs.apha.2016.03.002_bb0190","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.187.10.1575","article-title":"Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system","volume":"187","author":"Hawke","year":"1998","journal-title":"The Journal of Experimental Medicine"},{"issue":"147","key":"10.1016\/bs.apha.2016.03.002_bb0195","doi-asserted-by":"crossref","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta","volume":"4","author":"Iliff","year":"2012","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0200","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1227\/NEU.0000000000001020","article-title":"The value of 5-ALA in low-grade gliomas and high-grade gliomas lacking glioblastoma imaging features: An analysis based on fluorescence, MRI, 18F-FET PET, and tumor molecular factors","volume":"78","author":"Jaber","year":"2016","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0205","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","article-title":"Diffuse intrinsic pontine gliomas: A systematic update on clinical trials and biology","volume":"38","author":"Jansen","year":"2012","journal-title":"Cancer Treatment Reviews"},{"issue":"12","key":"10.1016\/bs.apha.2016.03.002_bb0210","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","article-title":"The glymphatic system: A Beginner's Guide","volume":"40","author":"Jessen","year":"2015","journal-title":"Neurochemical Research"},{"issue":"201","key":"10.1016\/bs.apha.2016.03.002_bb0215","doi-asserted-by":"crossref","first-page":"201ra119","DOI":"10.1126\/scitranslmed.3005954","article-title":"Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy","volume":"5","author":"Ji","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1089\/hum.1997.8.3-253","article-title":"Immune responses to adenoviral vectors during gene transfer in the brain","volume":"8","author":"Kajiwara","year":"1997","journal-title":"Human Gene Therapy"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0225","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/neuonc\/not310","article-title":"Glioma virus therapies between bench and bedside","volume":"16","author":"Kaufmann","year":"2014","journal-title":"Neuro-Oncology"},{"key":"10.1016\/bs.apha.2016.03.002_bb0230","first-page":"CD008218","article-title":"Antiangiogenic therapy for high-grade glioma","volume":"9","author":"Khasraw","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0235","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2990.1993.tb00476.x","article-title":"CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance","volume":"19","author":"Kida","year":"1993","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0240","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/mt.2008.18","article-title":"Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits","volume":"16","author":"King","year":"2008","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1215\/15228517-2007-045","article-title":"Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model","volume":"10","author":"King","year":"2008","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/bs.apha.2016.03.002_bb0250","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/mt.2011.77","article-title":"Combined Flt3L\/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen","volume":"19","author":"King","year":"2011","journal-title":"Molecular Therapy"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0255","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1227\/NEU.0b013e3181fa775b","article-title":"A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: Implications for physiological brain imaging of patients with intracranial tumors","volume":"67","author":"Kotsarini","year":"2010","journal-title":"Neurosurgery"},{"issue":"7549","key":"10.1016\/bs.apha.2016.03.002_bb0260","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0265","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ana.24271","article-title":"Impairment of paravascular clearance pathways in the aging brain","volume":"76","author":"Kress","year":"2014","journal-title":"Annals of Neurology"},{"issue":"11","key":"10.1016\/bs.apha.2016.03.002_bb0270","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1470-2045(11)70130-9","article-title":"Intraoperative MRI-guided resection of glioblastoma multiforme: A systematic review","volume":"12","author":"Kubben","year":"2011","journal-title":"The Lancet Oncology"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0275","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s11481-013-9470-8","article-title":"Drainage of cells and soluble antigen from the CNS to regional lymph nodes","volume":"8","author":"Laman","year":"2013","journal-title":"Journal of Neuroimmune Pharmacology"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"32","key":"10.1016\/bs.apha.2016.03.002_bb0285","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1073\/pnas.0913496107","article-title":"Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology","volume":"107","author":"Larocque","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2016.03.002_bb0290","first-page":"1","article-title":"A prospective phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas","volume":"6","author":"Lau","year":"2015","journal-title":"Journal of Neurosurgery"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0295","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1471-4906(01)02063-4","article-title":"Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective","volume":"23","author":"Lowenstein","year":"2002","journal-title":"Trends in Immunology"},{"issue":"2","key":"10.1016\/bs.apha.2016.03.002_bb0305","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0306-4522(96)00160-1","article-title":"The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system","volume":"74","author":"Matyszak","year":"1996","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-5728(97)00190-2","article-title":"Bacillus Calmette-Guerin sequestered in the brain parenchyma escapes immune recognition","volume":"82","author":"Matyszak","year":"1998","journal-title":"Journal of Neuroimmunology"},{"issue":"7","key":"10.1016\/bs.apha.2016.03.002_bb0315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1474-4422(05)70118-6","article-title":"Surgery for malignant gliomas: Mechanistic reasoning and slippery statistics","volume":"4","author":"Mitchell","year":"2005","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.apha.2016.03.002_bb0320","article-title":"Statistical considerations on prognostic models for glioma","author":"Molinaro","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0325","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11060-013-1338-5","article-title":"The role of cytotoxic chemotherapy in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline","volume":"118","author":"Olson","year":"2014","journal-title":"Journal of Neuro-Oncology"},{"issue":"17","key":"10.1016\/bs.apha.2016.03.002_bb0330","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: A clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-010-0360-0","article-title":"Stereotactic radiosurgery: A meta-analysis of current therapeutic applications in neuro-oncologic disease","volume":"103","author":"Pannullo","year":"2011","journal-title":"Journal of Neuro-Oncology"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0340","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.nurt.2009.04.011","article-title":"Oncolytic viral therapy of malignant glioma","volume":"6","author":"Parker","year":"2009","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0345","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/mt.2008.284","article-title":"Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented","volume":"17","author":"Peden","year":"2009","journal-title":"Molecular Therapy"},{"issue":"Suppl. 1","key":"10.1016\/bs.apha.2016.03.002_bb0350","first-page":"S86","article-title":"Persistent pathogens in the parenchyma of the brain","volume":"6","author":"Perry","year":"2000","journal-title":"Journal of Neurovirology"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0355","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","article-title":"Tissue concentration of systemically administered antineoplastic agents in human brain tumors","volume":"104","author":"Pitz","year":"2011","journal-title":"Journal of Neuro-Oncology"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0360","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1586\/erv.13.41","article-title":"An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma","volume":"12","author":"Reardon","year":"2013","journal-title":"Expert Review of Vaccines"},{"issue":"26","key":"10.1016\/bs.apha.2016.03.002_bb0365","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"1017","key":"10.1016\/bs.apha.2016.03.002_bb0370","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1259\/bjr\/83796755","article-title":"A clinical review of treatment outcomes in glioblastoma multiforme\u2014The validation in a non-trial population of the results of a randomised phase III clinical trial: Has a more radical approach improved survival?","volume":"85","author":"Rock","year":"2012","journal-title":"The British Journal of Radiology"},{"issue":"19","key":"10.1016\/bs.apha.2016.03.002_bb0375","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1073\/pnas.1417320112","article-title":"Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients","volume":"112","author":"Romano","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0380","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1227\/01.neu.0000318159.21731.cf","article-title":"Glioma extent of resection and its impact on patient outcome","volume":"62","author":"Sanai","year":"2008","journal-title":"Neurosurgery"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0385","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1586\/erv.11.49","article-title":"Heat shock protein-peptide complex in the treatment of glioblastoma","volume":"10","author":"See","year":"2011","journal-title":"Expert Review of Vaccines"},{"issue":"14","key":"10.1016\/bs.apha.2016.03.002_bb0390","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1089\/10430349950016979","article-title":"A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group","volume":"10","author":"Shand","year":"1999","journal-title":"Human Gene Therapy"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0395","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1148\/radiol.10100343","article-title":"Fiber density mapping of gliomas: Histopathologic evaluation of a diffusion-tensor imaging data processing method","volume":"257","author":"Stadlbauer","year":"2010","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0400","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.4049\/jimmunol.159.4.1876","article-title":"Virus dissemination through the brain parenchyma without immunologic control","volume":"159","author":"Stevenson","year":"1997","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0405","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1128\/JVI.71.1.145-151.1997","article-title":"The immunogenicity of intracerebral virus infection depends on anatomical site","volume":"71","author":"Stevenson","year":"1997","journal-title":"Journal of Virology"},{"issue":"10","key":"10.1016\/bs.apha.2016.03.002_bb0410","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0415","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/mthe.2000.0224","article-title":"Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain","volume":"3","author":"Thomas","year":"2001","journal-title":"Molecular Therapy"},{"issue":"13","key":"10.1016\/bs.apha.2016.03.002_bb0420","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1073\/pnas.120474397","volume":"97","author":"Thomas","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/bs.apha.2016.03.002_bb0425","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/104303401750148829","article-title":"Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors","volume":"12","author":"Thomas","year":"2001","journal-title":"Human Gene Therapy"},{"issue":"24","key":"10.1016\/bs.apha.2016.03.002_bb0430","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1523\/JNEUROSCI.19-24-10948.1999","article-title":"Cytomegalovirus cell tropism, replication, and gene transfer in brain","volume":"19","author":"van Den Pol","year":"1999","journal-title":"The Journal of Neuroscience"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0435","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1016\/bs.apha.2016.03.002_bb0440","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/WCO.0000000000000249","article-title":"Immunotherapy for glioblastoma: Concepts and challenges","volume":"28","author":"Weiss","year":"2015","journal-title":"Current Opinion in Neurology"},{"issue":"1","key":"10.1016\/bs.apha.2016.03.002_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-008-0457-0","article-title":"Lymphatic drainage of the brain and the pathophysiology of neurological disease","volume":"117","author":"Weller","year":"2009","journal-title":"Acta Neuropathologica"},{"issue":"3","key":"10.1016\/bs.apha.2016.03.002_bb0450","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1750-3639.1996.tb00855.x","article-title":"Lymphocyte targeting of the central nervous system: A review of afferent and efferent CNS-immune pathways","volume":"6","author":"Weller","year":"1996","journal-title":"Brain Pathology"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0455","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1750-3639.1992.tb00704.x","article-title":"Pathways of fluid drainage from the brain\u2014Morphological aspects and immunological significance in rat and man","volume":"2","author":"Weller","year":"1992","journal-title":"Brain Pathology"},{"issue":"7528","key":"10.1016\/bs.apha.2016.03.002_bb0460","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2016.03.002_bb0465","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1479-5876-11-107","article-title":"Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer","volume":"11","author":"Yang","year":"2013","journal-title":"Journal of Translational Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2016.03.002_bb0470","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/mt.2011.243","article-title":"Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNgamma, perforin, and TNFalpha, and due to the elimination of transduced cells","volume":"20","author":"Zirger","year":"2012","journal-title":"Molecular Therapy"}],"container-title":["Advances in Pharmacology","Neuropsychopharmacology: A Tribute to Joseph T. Coyle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358916300229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358916300229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T21:26:58Z","timestamp":1692307618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358916300229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9780128097458"],"references-count":94,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2016.03.002","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}